Who is sponsoring NCT00659594?

NCT00659594 is sponsored by AstraZeneca.

What condition does NCT00659594 study?

NCT00659594 studies Rhinitis, Allergic, Seasonal, Hay Fever.

What drugs are being tested in NCT00659594?

Interventions: Ciclesonide, Placebo.

What is the status of NCT00659594?

NCT00659594 is currently COMPLETED.

Last reviewed 2016-12-01 · How we verify

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray (200 mg, Once Daily), in the Treatment of Seasonal Allergic Rhinitis (SAR) in Patients 18 Years and Older

NCT00659594 Phase 3 COMPLETED

The primary objective of this placebo-controlled EEC study is to determine the time to onset of action of ciclesonide, applied as a nasal spray (200 mg, once daily) in patients with SAR.

Details

Lead sponsor	AstraZeneca
Phase	Phase 3
Status	COMPLETED
Enrolment	500
Start date	2004-11
Completion	2005-09

Conditions

Rhinitis, Allergic, Seasonal
Hay Fever

Interventions

Ciclesonide
Placebo

Primary outcomes

Time to onset of action, measured by a difference from placebo in the change from baseline in patient -assessed instantaneous TNSS following treatment — 14 hours

Countries

Canada